Free Newsletter
Vaccine makers settle France's H1N1 bill
A newspaper has reported that France has struck a deal to pay several large vaccine makers just 16 percent of the amount it had contracted to pay after canceling a huge order of swine flu vaccine. According to Le Figaro, Novartis, GlaxoSmithKline and Sanofi will get €48 million in payment for €358 million of vaccine that the country had ordered and then cancelled. GSK will face the steepest loss from the cancellation. A number of European countries were stuck with large supplies of H1N1 vaccine after the pandemic turned out to be milder than anticipated and a huge portion of their populations shunned the jab. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
More Research Reports >>
SHARE
WITH: